Performance of Bioresorbable Polymer-Coated Everolimus-Eluting Synergy® Stent in Patients at High Bleeding Risk Undergoing Percutaneous Coronary Revascularization Followed by 1-Month Dual Antiplatelet Therapy
Phase of Trial: Phase IV
Latest Information Update: 21 Sep 2018
At a glance
- Drugs Everolimus (Primary) ; Aspirin
- Indications Acute coronary syndromes; Angina pectoris; Coronary artery disease; Ischaemia
- Focus Adverse reactions
- Acronyms POEM
- 08 Aug 2018 Planned primary completion date changed from 1 May 2018 to 1 May 2019.
- 17 Aug 2017 Status changed from not yet recruiting to recruiting.
- 19 Apr 2017 New trial record